ClinicalTrials.gg
Not yet recruitingNCT07482956Updated Mar 19, 2026

BCC-One-Stop-Study

An interventional study of Margin Mapping with Line-field confocal optical coherence tomography in Basal Cell Carcinoma, sponsored by University Hospital Augsburg. Not yet recruiting at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by University Hospital Augsburg · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Carcinoma, Basal Cell with a site in Germany — 7 open to participants now, 8 under way, none of them phase 3. Carcinoma, Basal Cell · Germany.

Planned enrollment
3rd of 22
290 · median 106
Started
2026
with 3 others
No phase
2 of 31
1 open now
Registered
30th of 31
by date

Among the 31 studies in Carcinoma, Basal Cell with a site in Germany, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 with no phase, and was the 30th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

7 of the 31 studies in Carcinoma, Basal Cell with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Carcinoma, Basal Cell with a site in Germany, or all of them as a file.
02

Study summary

Basal cell carcinoma (BCC) is the most common malignant skin tumour. The standard treatment is micrographically controlled surgery (MMS), which achieves high cure rates but requires considerable time and personnel. A key problem is the inadequate preoperative determination of tumour margins, which often leads to multiple cycles of excision.

The aim of this multicentre, prospective, randomised controlled intervention study is to evaluate line-field confocal optical coherence tomography (LC-OCT) for preoperative margin determination in BCC within the framework of MMS.

Research question:

Can preoperative LC-OCT-assisted margin marking increase the efficiency of MMS by reducing the number of excision cycles required without compromising oncological safety?

Methodology:

Approximately 290 patients with histologically confirmed BCC will be enrolled at five German centres and randomly assigned to either standard MMS or MMS with upstream LC-OCT margin determination. In the intervention group, the excision margin will be specifically extended if a tumour is detected in the LC-OCT.

Primary endpoint:

Number of MMS cycles required to achieve R0 resection.

Secondary endpoints:

Total duration of surgery, size of surgical defect, cosmetic outcome (POSAS), patient satisfaction and stress, sensitivity and specificity of LC-OCT compared to histopathology.

Significance:

The study addresses the clinical conflict of objectives between complete tumour removal and maximum tissue preservation. Successful implementation could optimise MMS through modern imaging, conserve surgical resources and improve patient care in the long term.

Read the detailed description

Basal cell carcinoma (BCC) is the most common type of skin cancer worldwide and occurs predominantly in fair-skinned populations. In Germany, approximately one in three individuals will develop BCC during their lifetime. Although BCC rarely metastasizes, it shows locally destructive growth with irregular, finger-like extensions into surrounding tissue, which can make complete surgical removal challenging. The majority of tumors arise in the sun-exposed head and neck region.

Micrographic surgery (Mohs micrographic surgery, MMS) represents the gold standard treatment for high-risk BCC, as it allows complete margin control and offers the highest cure rates. However, MMS is often time-consuming and resource-intensive because multiple sequential excision stages may be required until histopathology confirms complete tumor removal (R0 resection). Preoperative estimation of tumor margins is usually based on clinical examination and dermoscopy with a standard safety margin of 2-3 mm. This approach may be inaccurate, particularly in tumors with subclinical extension, which can lead either to unnecessarily large excisions or to residual tumor tissue requiring additional surgical stages.

Non-invasive imaging techniques have increasingly been investigated to improve the preoperative assessment of BCC margins. Optical coherence tomography (OCT) and the more recently developed line-field confocal optical coherence tomography (LC-OCT) allow high-resolution, real-time imaging of the skin. These technologies enable visualization of skin structures with near-histological resolution and can detect characteristic morphological features of BCC in vivo. Previous studies have demonstrated good diagnostic accuracy of OCT and LC-OCT for the detection and subtyping of BCC and suggest that these methods may also be useful for defining tumor margins before surgery.

In particular, LC-OCT combines the advantages of conventional OCT with the cellular resolution of confocal microscopy, allowing both vertical and horizontal imaging of the skin at high resolution. This enables detailed visualization of tumor architecture and potentially facilitates the detection of subclinical tumor extensions beyond the clinically visible borders.

The present multicenter randomized controlled study aims to evaluate whether LC-OCT-guided preoperative margin assessment can improve the efficiency of MMS. In the intervention group, the lateral tumor margins are examined preoperatively using LC-OCT. If tumor structures are detected at the planned resection margin, the surgical margin is extended accordingly before the first excision step. MMS is then performed according to the standard surgical protocol with histopathological examination of the margins. In centers where available, excised tissue may additionally be examined postoperatively using ex vivo LC-OCT or confocal microscopy to correlate imaging findings with histopathology.

The study investigates whether this image-guided approach can reduce the number of surgical stages required to achieve complete tumor removal, while maintaining oncological safety. By enabling more accurate preoperative mapping of tumor margins, LC-OCT-guided surgery may improve surgical planning and increase the likelihood of complete excision in the first stage of MMS. In addition, improved margin delineation could allow more tissue-sparing surgery, potentially leading to smaller surgical defects and better cosmetic outcomes.

Overall, this study evaluates the clinical utility of integrating LC-OCT into the surgical workflow of MMS. The results may provide evidence for a more efficient and resource-conserving surgical strategy in the treatment of basal cell carcinoma while maintaining the high oncological safety standards of micrographic surgery.

03

Conditions studied

  • Basal Cell Carcinoma

Keywords

  • basal cell carcinoma
  • line-field confocal optical coherence tomography
  • BCC
  • LC-OCT
  • Mohs micrographic surgery
  • MMS
  • margin mapping
  • margin assessment
  • skin cancer
  • one stop shop
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with basal cell carcinoma (BCC) scheduled for Mohs micrographic surgery (MMS),
  • Diagnosis confirmed by dermoscopy and histopathology or optical coherence tomography (OCT),
  • No limitation regarding tumor size or BCC subgroups.

Exclusion criteria

Exclusion Criteria:

  • Poor LC-OCT image quality,
  • Incomplete adherence to the study protocol,
  • Previous treatment of the BCC,
  • Anatomical sites that are difficult to access with LC-OCT (e.g., inner ear, medial canthus of the eye).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
290 participants (estimated)

Study arms

  • Experimental
    Intervention group (LC-OCT)

    Preoperative tumour margin assessment using LC-OCT with targeted extension of resection margins in cases where imaging reveals tumour evidence.

    Diagnostic Test: Margin Mapping with Line-field confocal optical coherence tomography

  • No intervention
    Control group (standard MMS)

    Conventional clinical/dermatoscopic margin determination, as is customary in everyday clinical practice.

Interventions

  • Diagnostic testMargin Mapping with Line-field confocal optical coherence tomography

    Both groups undergo micrographically controlled excision (Mohs surgery) in accordance with standard procedure. Surgical margins are examined histopathologically as usual (e.g. Tübingen cake, Munich method). If tumour remnants are detected, re-excision (MMS cycle) is performed until the tumour is completely removed (R0). The difference in the intervention group is that they will receive preoperative (and if available) postoperative margin mapping of the BCC before surgery.

06

What researchers measure

Primary outcomes

  1. Number of surgical excision cycles (MMS cycles) required until complete tumour removal

    Primary endpoints: Number of surgical excision cycles (MMS cycles) required until complete tumour removal (R0 status). This target parameter is directly related to the main question of whether preoperative margin assessment using LC-OCT increases the efficiency of MMS. A significant difference (e.g. fewer MMS cycles in the intervention group) would prove that the image-guided procedure is more effective.

    Time frame: On the day of surgery (Day 0), after the first histopathological margin assessment

Secondary outcomes

  1. Total duration of the surgical procedure

    Total duration of the surgical procedure (in minutes) → Recorded from the incision to the end of the operation.

    Time frame: intraoperatively, on the day of surgery (Day 0)

  2. Area of the surgical defect after complete tumour removal

    Area of the surgical defect after complete tumour removal (in cm²) → Documented for the purpose of assessing tissue preservation.

    Time frame: after the last excision, before wound closure

  3. Cosmetic outcome of the scar

    Cosmetic outcome of the scar (e.g. using Patient and Observer Scar Assessment Scale (POSAS)). The observer scale of the POSAS consists of six items (vascularity, pigmentation, thickness, relief, pliability and surface area). All items are scored on a scale ranging from 1 ('like normal skin') to 10 ('worst scar imaginable'). The sum of the six items results in a total score of the POSAS observer scale. Categories boxes are added for each item. Furthermore, an overall opinion is scored on a scale ranging from 1 to 10. All parameters should preferably be compared to normal skin on a comparable anatomic location. → Assessment after a defined post-operative period.

    Time frame: at follow-up 2, approx. week 6-12

  4. Patient satisfaction

    Patient satisfaction → Determined by validated questionnaire (e.g. Likert scale for subjective evaluation of the process and result). A 5-point Likert scale is a popular rating scale for surveys that uses five options to measure opinions, attitudes, or perceptions, typically ranging from "Strongly Disagree" to "Strongly Agree," with a neutral option in the middle.

    Time frame: week 6-12

  5. Correlation between LC-OCT findings and histopathological margin status

    Correlation between LC-OCT findings and histopathological margin status → Specification of sensitivity, specificity, positive and negative predictive value of LC-OCT.

    Time frame: within 7 days after surgery

  6. Number of unexpected tumour detections in peripheral areas originally assessed as tumour-free

    Number of unexpected tumour detections in peripheral areas originally assessed as tumour-free → Evaluation of the diagnostic reliability of LC-OCT.

    Time frame: within 7 days after surgery

  7. Occurrence of complications or adverse events

    Occurrence of complications or adverse events (e.g. delayed wound healing, infection) → To assess the safety of the procedure.

    Time frame: until completion of the second follow-up (i.e., by week 6-12)

Other outcomes

  1. The proportion of each BCC subtype (nodular, superficial, or infiltrative BCC) if BCC was not excised in a one-step operation.

    For lesions in which (LC)-OCT margin assessment did not result in a one-step operation, the proportion of each BCC subtype (nodular, superficial, or infiltrative BCC) should be determined.

    Time frame: within 7 days after surgery

  2. the proportion of BCCs whose margins in the first surgical step were not tumor-free (i) laterally and (ii) in depth if BCC was not excised in a one-step operation.

    For lesions in which (LC)-OCT margin assessment did not result in a one-step operation, the proportion of BCCs whose margins in the first surgical step were not tumor-free (i) laterally and (ii) in depth should be determined.

    Time frame: within 7 days after surgery

  3. Anatomical Location of Skin Lesions Assessed by LC-OCT Imaging

    For lesions in which (LC)-OCT margin assessment did not result in a one-step operation, it should be assessed, whether the anatomical location had an influence. The anatomical location of each included skin lesion will be documented using standardized dermatological body site mapping (International Classification of Anatomical Sites for Dermatology). Assessment will be performed by line-field confocal optical coherence tomography (LC-OCT), which provides high-resolution vertical and horizontal images of epidermal and dermal structures. For each lesion, the exact body site (e.g., face - nasal sidewall; trunk - upper back; extremities - dorsal forearm) will be recorded according to the predefined anatomical site categories.

    Time frame: Baseline (Day 0)

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Aug 2026, 4 months later.

Of 50 interventional studies with no phase under Carcinoma, Basal Cell, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 64. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Mar 19, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482956
Lead sponsor
University Hospital Augsburg
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Julia Welzel, MD
Contact
julia.welzel@uk-augsburg.de
00498214007401
Sandra Schuh, MD, M.Sc.
Contact
sandra.schuh@uk-augsburg.de
0049821400167508
Julia Welzel, MD
principal investigator · University Hospital Augsburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion